Inhalon Biopharma
Inhalon Biopharma is a clinical-stage biotechnology company focused on developing innovative inhaled antibody treatments for acute respiratory infections. Their mission is to provide effective and convenient treatment options for conditions such as RSV, hMPV, influenza, and SARS-CoV-2, utilizing a unique 'test-to-treat' model that enhances patient care.
Industries
Nr. of Employees
small (1-50)
Inhalon Biopharma
Awards
Military Prototype Advancement Initiative (MPAI)
IN-007: An Inhaled ACE2-Targeting Therapeutic Prototype for Pandemic Preparedness
Funding (ceiling)
$6,387,048
Award Year
2023
Production and Phase 1/2a trial of Inhaled Immunotherapy for COVID‐19
Funding (ceiling)
$6,913,224
Award Year
2020
Products
Inhaled monoclonal antibody candidates for acute respiratory infections
A pipeline of inhaled antibody therapeutics developed for direct delivery to the lung to treat or prevent acute respiratory infections including RSV, SARS-CoV-2, human metapneumovirus (hMPV), and influenza.
Inhaled monoclonal antibody candidates for acute respiratory infections
A pipeline of inhaled antibody therapeutics developed for direct delivery to the lung to treat or prevent acute respiratory infections including RSV, SARS-CoV-2, human metapneumovirus (hMPV), and influenza.
Expertise Areas
- Inhaled therapeutics for acute respiratory infections
- Monoclonal antibody engineering and glycoengineering
- Pulmonary drug delivery and aerosolization
- Preclinical animal models for respiratory viruses (large- and small-animal)
Key Technologies
- Handheld vibrating nebulizer aerosol delivery
- Muco-trapping antibody mechanism
- Inhaled monoclonal antibody formulations
- ACE2-based decoy biologics
Key People
Featured In Technology Showcase
Developing a Self-administered, Fast-acting Inhaled Immunotherapy for COVID-19
Inhalon Biopharma and Celltrion's lead candidate, IN-006, has shown safety and prolonged lung retention in Phase 1 trials, offering a self-administered, fast-acting solution for COVID-19 and other viral threats.
News & Updates
Inhalon Biopharma will present its findings at the Military Health System Research Symposium.
An update on the inhaled monoclonal antibody therapy platform will be provided at the BIO International Convention.
Inhalon will share progress on its inhaled monoclonal antibody therapy at the congress.
Positive results from a study showing the advantages of Inhalon's inhaled antibody platform over traditional systemic dosing.
Inhalon announces two new publications that advance its inhaled antibody treatment platform.
Inhalon will present its product development pipeline at the Biotech Showcase.
Inhalon Biopharma will present its findings at the Military Health System Research Symposium.
An update on the inhaled monoclonal antibody therapy platform will be provided at the BIO International Convention.
Inhalon will share progress on its inhaled monoclonal antibody therapy at the congress.
Positive results from a study showing the advantages of Inhalon's inhaled antibody platform over traditional systemic dosing.
Inhalon announces two new publications that advance its inhaled antibody treatment platform.
Inhalon will present its product development pipeline at the Biotech Showcase.